

K973780

P172

NOV 26 1997

**9. 510 (k) Summary of Information Respecting Safety and Effectiveness**

**A. Legally Marketed Device.**

Qualis claims substantial equivalence to KY Liquid (K790087), currently in commercial distribution by Ortho Pharmaceutical Corp.

**B. Device Description.**

Personal Lubricating Liquid is a water-based, nonsticky, nonstaining personal lubricant that is compatible with condoms and diaphragms.

**C. Intended Use.**

Personal Lubricating Liquid is designed to enhance the ease and comfort of intimate activity and is compatible with latex condoms.

**D. Comparison with Predicate Device.**

A summary comparison of the features of Personal Lubricating Liquid and the Predicate Device (KY Liquid) is provided in Table 1.

**E. Performance Data.**

**Non-clinical studies.**

**1. Stability.**

Personal Lubricating Liquid successfully passed the requirements of the Qualis, Inc., accelerated stability protocol and has been assigned a two-year expiration period.

**2. Preservative Effectiveness.**

Personal Lubricating Liquid successfully passed the requirements of the Qualis, Inc., antimicrobial preservative challenge.

K973780

P272

3. Comparison with Predicate Device.

Personal Lubricating Liquid was compared to KY Liquid on the basis of perceptual qualities, physical and chemical properties, ingredients list review, label claims, and packaging. The result of this review was a "Good" comparison.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

NOV 26 1997

Mary A. Finn, Ph.D.  
Director - Compliance and Regulatory Affairs  
QUALIS, Inc.  
4600 Park Avenue  
Des Moines, Iowa 50321

Re: K973780  
Personal Lubricating Liquid (Patient Lubricant)  
Dated: September 5, 1997  
Received: October 3, 1997  
Regulatory class: II  
21 CFR §884.5300/Product code: 85 HIS

Dear Dr. Finn:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsmamain.html>.

Sincerely yours,

Lillian Yin, Ph.D.  
Director, Division of Reproductive,  
Abdominal, Ear, Nose and Throat,  
and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

